Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zheng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Fengqin Xiong
State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication- Hao Wang
China State Institute of Pharmaceutical Industry, Shanghai 201203, China
1 shared publication - Helen He Zhu
State Key Laboratory of Systems Medicine for Cancer, Department of Urology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China
1 shared publication Lingli Zhou
State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publicationLinyang Jiang
State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication- Pengcheng Zhang
School of Biomedical Engineering, ShanghaiTech University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (23) , eadk9996
Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles
Immunotoxicity remains a major hindrance to chemotherapy in cancer therapy. Nanocarriers may alleviate the immunotoxicity, but the optimal design remains unclear. Here, we created two variants of maytansine (DM1)–loaded synthetic high-density lipoproteins (D-sHDL) with either physically entrapped ( E D-sHDL) or chemically conjugated ( C D-sHDL) DM1. We found that C D-sHDL showed less accumulation in the tumor draining lymph nodes (DLNs) and femur, resulting in a lower toxicity against myeloid cells than E D-sHDL via avoiding scavenger receptor class B type 1 (SR-B1)–mediated DM1 transportation into the granulocyte-monocyte progenitors and dendritic cells. Therefore, higher densities of lymphocytes in the tumors, DLNs, and blood were recorded in mice receiving C D-sHDL, leading to a better efficacy and immune memory of C D-sHDL against colon cancer. Furthermore, liposomes with conjugated DM1 ( C D-Lipo) showed lower immunotoxicity than those with entrapped drug ( E D-Lipo) through the same mechanism after apolipoprotein opsonization. Our findings highlight the critical role of drug loading patterns in dictating the biological fate and activity of nanomedicine.
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (23) , eadk9996
Open AccessChemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles
Immunotoxicity remains a major hindrance to chemotherapy in cancer therapy. Nanocarriers may alleviate the immunotoxicity, but the optimal design remains unclear. Here, we created two variants of maytansine (DM1)–loaded synthetic high-density lipoproteins (D-sHDL) with either physically entrapped ( E D-sHDL) or chemically conjugated ( C D-sHDL) DM1. We found that C D-sHDL showed less accumulation in the tumor draining lymph nodes (DLNs) and femur, resulting in a lower toxicity against myeloid cells than E D-sHDL via avoiding scavenger receptor class B type 1 (SR-B1)–mediated DM1 transportation into the granulocyte-monocyte progenitors and dendritic cells. Therefore, higher densities of lymphocytes in the tumors, DLNs, and blood were recorded in mice receiving C D-sHDL, leading to a better efficacy and immune memory of C D-sHDL against colon cancer. Furthermore, liposomes with conjugated DM1 ( C D-Lipo) showed lower immunotoxicity than those with entrapped drug ( E D-Lipo) through the same mechanism after apolipoprotein opsonization. Our findings highlight the critical role of drug loading patterns in dictating the biological fate and activity of nanomedicine.